Recent Progress on Affibody-Based Supramolecular Architectures: Moving from Monomeric Constructs to Multivalent Assemblies

Affibody molecules have emerged as versatile protein engineering platforms due to their exceptional binding properties. These small (6.5 kDa) three-helix bundle proteins, derived from the Z-domain of Staphylococcal protein A, can be engineered to bind diverse molecular targets with high affinity and specificity. This structural and functional versatility has driven their applications in diagnostics, therapeutics, and biosensing. This review examines the evolution from monomeric affibody constructs to multivalent supramolecular assemblies, highlighting how this shift overcomes key limitations while expanding functionality. Recent advances in conjugation chemistry, scaffold engineering, and protein design have enabled sophisticated affibody-based architectures with enhanced pharmacokinetic profiles and multivalent binding capabilities, thereby improving their utility in targeted drug delivery, molecular imaging, and theranostics.

• Publication year

  2025

• Venue

  Pharmaceuticals

• Publication date

  2025-11-01

• Fields of study

  Medicine, Materials Science, Chemistry

• Identifiers
  DOI 10.3390/ph18111669PMID 41304914PMCID 12655228
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An Affibody-Cytotoxin Conjugate-Based Nanoagent for EGFR Targeting and Precise Therapy of Epidermal Squamous Cell Carcinoma

  2025influential reference
• Recent advances of affibody molecules in biomedical applications.

  2024cited by this paper
• Developing Porous Protein Cage Nanoparticles as Cargo-Loadable and Ligand-Displayable Modular Delivery Nanoplatforms.

  2024cited by this paper
• A self-assembled affibody-PROTAC conjugate nanomedicine for targeted cancer therapy

  2024cited by this paper
• Affibody-Functionalized Elastin-like Peptide-Drug Conjugate Nanomicelle for Targeted Ovarian Cancer Therapy.

  2024cited by this paper
• A novel HER2 targeting nanoagent self-assembled from affibody-epothilone B conjugate for cancer therapy

  2024influential reference
• Amphiphilic Affibody-PROTAC conjugate Self-Assembled nanoagents for targeted cancer therapy

  2024cited by this paper
• Half-life extension via ADB-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.

  2024cited by this paper
• Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy

  2024cited by this paper
• Protein-Precoated Surface of Metal-Organic Framework Nanoparticles for Targeted Delivery.

  2023cited by this paper
• CytoDirect: A Nucleic Acid Nanodevice for Specific and Efficient Delivery of Functional Payloads to the Cytoplasm.

  2023cited by this paper
• Supramolecular Chemistry: Unveiling the Fascinating World of Non-Covalent Interactions and Complex Assemblies

  2023cited by this paper
• Phase I clinical evaluation of 99mTc-labeled Affibody molecule for imaging HER2 expression in breast cancer

  2023cited by this paper
• Engineering of Affibody Molecules.

  2023cited by this paper
• Moderate‐Affinity Affibodies Modulate the Delivery and Bioactivity of Bone Morphogenetic Protein‐2

  2023cited by this paper
• Virus-like nanoparticles as a theranostic platform for cancer

  2023cited by this paper
• Development of active affibody aggregates induced by a self-assembling peptide for high sensitive detection of alpha-fetoprotein

  2022influential reference
• TRAIL & EGFR affibody dual-display on a protein nanoparticle synergistically suppresses tumor growth.

  2022cited by this paper
• Directed Evolution Enables Simultaneous Controlled Release of Multiple Therapeutic Proteins from Biopolymer‐Based Hydrogels

  2022cited by this paper
• Application of a Novel 68Ga-HER2 Affibody PET/CT Imaging in Breast Cancer Patients

  2022cited by this paper
• Photothermal Therapy with HER2-Targeted Silver Nanoparticles Leading to Cancer Remission

  2022cited by this paper
• Affibody Modified G-quadruplex DNA Micelles Incorporating Polymeric 5-Fluorodeoxyuridine for Targeted Delivery of Curcumin to Enhance Synergetic Therapy of HER2 Positive Gastric Cancer

  2022cited by this paper
• The Combined Effect of Nanobubble-IR783-HPPH-Affibody Complex and Laser on HER2-Positive Breast Cancer

  2022cited by this paper
• Multivalent display of chemical signals on self‐assembled peptide scaffolds

  2021cited by this paper
• Self-Assembled Nanomicelles of Affibody-Drug Conjugate with Excellent Therapeutic Property to Cure Ovary and Breast Cancers

  2021influential reference
• Engineering Saccharomyces cerevisiae for the production and secretion of Affibody molecules

  2021cited by this paper
• Near-infrared PbS quantum dots functionalized with affibodies and ZnPP for targeted imaging and therapeutic applications

  2021cited by this paper
• Discovery, optimization and biodistribution of an Affibody molecule for imaging of CD69

  2021cited by this paper
• PLGA Nanoparticles Decorated with Anti-HER2 Affibody for Targeted Delivery and Photoinduced Cell Death

  2021cited by this paper
• Target-switchable Gd(III)-DOTA/protein cage nanoparticle conjugates with multiple targeting affibody molecules as target selective T1 contrast agents for high-field MRI.

  2021cited by this paper
• Highway to Success—Developing Advanced Polymer Therapeutics

  2021cited by this paper
• Affibody Molecules as Targeting Vectors for PET Imaging

  2020cited by this paper
• Affibody-Conjugated RALA Polymers Delivering Oligomeric 5-Fluorodeoxyuridine for Targeted Therapy of HER2 Overexpressing Gastric Cancer.

  2020cited by this paper
• PET imaging of a 68Ga labeled modified HER2 affibody in breast cancers: from xenografts to patients.

  2019cited by this paper
• Multivalent HER2-binding polymer conjugates facilitate rapid endocytosis and enhance intracellular drug delivery.

  2019cited by this paper
• Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications

  2018cited by this paper
• Affibody-functionalized Ag2S quantum dots for photoacoustic imaging of epidermal growth factor receptor overexpressed tumors.

  2018cited by this paper
• Supramolecular Nanofibers of Drug‐Peptide Amphiphile and Affibody Suppress HER2+ Tumor Growth

  2018cited by this paper
• Sensitive detection of dengue virus NS1 by highly stable affibody-functionalized gold nanoparticles

  2018cited by this paper
• Surface functionalization of polymeric nanoparticles for tumor drug delivery: approaches and challenges

  2017cited by this paper
• Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells.

  2017cited by this paper
• Affibody Molecules in Biotechnological and Medical Applications.

  2017cited by this paper
• Affibody molecules as engineered protein drugs

  2017influential reference
• Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT

  2016cited by this paper
• Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin.

  2016cited by this paper
• Nanobubble-Affibody: Novel ultrasound contrast agents for targeted molecular ultrasound imaging of tumor.

  2015influential reference
• Analytical applications of affibodies

  2015cited by this paper
• Multifunctional nanoparticles for use in theranostic applications

  2015cited by this paper
• First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule

  2014cited by this paper
• Affibody modified and radiolabeled gold-iron oxide hetero-nanostructures for tumor PET, optical and MR imaging.

  2013cited by this paper
• Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule–Albumin-Binding Domain Fusion Protein

  2013cited by this paper
• Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule.

  2013cited by this paper
• Engineering of affibody molecules for therapy and diagnostics.

  2012cited by this paper
• Ribosome Display Selection of a Murine IgG1 Fab Binding Affibody Molecule Allowing Species Selective Recovery Of Monoclonal Antibodies

  2011cited by this paper
• Molecular Design and Optimization of 99mTc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties

  2011cited by this paper
• Affibody-based nanoprobes for HER2-expressing cell and tumor imaging.

  2011influential reference
• Affibody-functionalized gold-silica nanoparticles for Raman molecular imaging of the epidermal growth factor receptor.

  2011cited by this paper
• N‐terminal engineering of amyloid‐β‐binding Affibody molecules yields improved chemical synthesis and higher binding affinity

  2010cited by this paper
• Nanoparticle-based theragnostics: Integrating diagnostic and therapeutic potentials in nanomedicine.

  2010cited by this paper
• Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications

  2010cited by this paper
• Design of an optimized scaffold for affibody molecules.

  2010cited by this paper
• Engineered affinity proteins--generation and applications.

  2009cited by this paper
• Update: Affibody Molecules for Molecular Imaging and Therapy for Cancer

  2007cited by this paper
• Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor.

  2007cited by this paper
• Effects of HER2-Binding Affibody Molecules on Intracellular Signaling Pathways

  2006cited by this paper
• Structural basis for molecular recognition in an affibody:affibody complex.

  2006cited by this paper
• Tumor imaging using a picomolar affinity HER2 binding affibody molecule.

  2006cited by this paper
• Chemical Synthesis of Triple‐Labelled Three‐Helix Bundle Binding Proteins for Specific Fluorescent Detection of Unlabelled Protein

  2005cited by this paper
• An affibody in complex with a target protein: Structure and coupled folding

  2003influential reference
• Structural basis for recognition by an in vitro evolved affibody

  2003cited by this paper
• Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain

  1997influential reference
• Humanization of an anti-p185HER2 antibody for human cancer therapy.

  1992cited by this paper

• No citing papers are available for this paper.